Trends in the ASCVD, LDL-C Management Treatment Landscape in 2022
January 27th 2022Norman Lepor, MD, a cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), discusses major trends in the atherosclerotic cardiovascular disease and LDL-C management treatment landscape this year.
The Shifting Health Care Landscape for Pharmacy Technicians
January 27th 2022Expert panel discusses the current state of the pharmacy technician role, how COVID-19 changed the perception of pharmacy technicians, and updates across the legislative and regulatory landscape for pharmacy technician–administered tests and vaccines.
The Mechanism of Action of Inclisiran for LDL-C Management in ASCVD
January 21st 2022Norman Lepor, MD, a cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), discussed inclisiran’s mechanism of action and how it supports LDL-C management for patients with ASCVD.
The Impact of the Pandemic on the Advancement of Data Interoperability, Drug Development
January 20th 2022Shreejit Nair, senior vice president and life sciences market business lead at CitiusTech, discussed what the impact of the pandemic has been on the advancement of data interoperability in health care.
How Inclisiran Helps to Manage LDL-C for Patients With ASCVD
January 20th 2022Norman Lepor, MD, a cardiologist and clinical investigator in the phase 3 clinical program for inclisiran, discussed the trial results assessing the efficacy and safety of inclisiran for patients with atherosclerotic cardiovascular disease.